ATE453403T1 - Wirtszelle enthaltend ein rekombinantes virus, welches ein antigen exprimiert und ein rekombinantes virus, welches ein immunstimulatorisches molekül exprimiert - Google Patents

Wirtszelle enthaltend ein rekombinantes virus, welches ein antigen exprimiert und ein rekombinantes virus, welches ein immunstimulatorisches molekül exprimiert

Info

Publication number
ATE453403T1
ATE453403T1 AT00102998T AT00102998T ATE453403T1 AT E453403 T1 ATE453403 T1 AT E453403T1 AT 00102998 T AT00102998 T AT 00102998T AT 00102998 T AT00102998 T AT 00102998T AT E453403 T1 ATE453403 T1 AT E453403T1
Authority
AT
Austria
Prior art keywords
recombinant virus
expresses
antigen
host cell
immuno
Prior art date
Application number
AT00102998T
Other languages
English (en)
Inventor
Jeffrey Schlom
Judith Kantor
James W Hodge
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE453403T1 publication Critical patent/ATE453403T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00102998T 1994-10-03 1995-10-02 Wirtszelle enthaltend ein rekombinantes virus, welches ein antigen exprimiert und ein rekombinantes virus, welches ein immunstimulatorisches molekül exprimiert ATE453403T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31726894A 1994-10-03 1994-10-03
US08/483,316 US6045802A (en) 1994-10-03 1995-06-07 Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule

Publications (1)

Publication Number Publication Date
ATE453403T1 true ATE453403T1 (de) 2010-01-15

Family

ID=23232884

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00102998T ATE453403T1 (de) 1994-10-03 1995-10-02 Wirtszelle enthaltend ein rekombinantes virus, welches ein antigen exprimiert und ein rekombinantes virus, welches ein immunstimulatorisches molekül exprimiert

Country Status (5)

Country Link
US (2) US6045802A (de)
EP (1) EP2153846A1 (de)
AT (1) ATE453403T1 (de)
DE (1) DE69536039D1 (de)
ES (1) ES2336069T3 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
EP0814838B1 (de) * 1995-03-08 2003-05-14 The Scripps Research Institute Antigen präsentierendes system und aktivierung von t-zellen
US6969609B1 (en) * 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
US7279168B2 (en) * 1998-05-01 2007-10-09 Texas A & M University System Recombinant virus expressing foreign DNA encoding feline CD86 and uses thereof
DE69919869T2 (de) * 1998-06-10 2005-09-29 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Stimulierung des immunsystems
AU1013601A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
ATE346925T1 (de) * 2000-05-10 2006-12-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
AU2001272978A1 (en) * 2000-06-23 2002-01-08 Maxygen, Inc. Novel co-stimulatory molecules
US7183376B2 (en) * 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
AU2001291162A1 (en) 2000-09-25 2002-04-08 Regents Of The University Of Michigan Production of viral vectors
US6892140B1 (en) * 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
US8058248B2 (en) * 2001-04-26 2011-11-15 The United States Of America As Represented By The Secretary Of Agriculture Foot and mouth disease virus vaccine comprising interferons
US20040091995A1 (en) * 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
EP1281767A3 (de) * 2001-07-31 2003-05-28 Aladar A. Szalay Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren
AU2002336522A1 (en) * 2001-09-14 2003-04-01 Baylor College Of Medicine Compositions and methods for t cell priming and immunotherapy
US7247297B2 (en) * 2001-09-14 2007-07-24 The University Of Chicago Use of DF3/MUC1 regulated expression in gene therapy
AU2002364161A1 (en) * 2001-12-12 2003-06-23 Aventis Pasteur Limited Enhancement of the immune response using cd36-binding domain
ATE369895T1 (de) 2002-04-09 2007-09-15 Sanofi Pasteur Ltd Modifizierte cea nucleinsäure und expressionsvektoren
US20070178065A1 (en) * 2002-05-03 2007-08-02 Lattime Edmund C Neutralizing factors as vaccine adjuvants
EP1369491A1 (de) * 2002-06-05 2003-12-10 Aladar A. Szalay Lichtemittierende Mikroorganismen und Zellen für die Diagnose und Therapie von Krankheiten assoziiert mit Wunden oder entzündetem Gewebe
US20040101522A1 (en) * 2002-09-12 2004-05-27 Therion Biologics Corporation Transduced neoplastic cell preparations able to express T-cell costimulatory molecules B7.1, ICAM-1, and LFA-3 and induce immunostimulatory prophylactic and therapeutic anti-tumor effects in-vivo
AU2003278036B2 (en) * 2002-10-22 2009-12-10 Aventis Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
AU2003297499A1 (en) * 2002-12-23 2004-07-22 City Of Hope Modified vaccinia ankara expressing p53 in cancer immunotherapy
EP1601333B1 (de) 2003-02-20 2013-01-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Neue einführungsstellen in pocken-vektoren
WO2005047458A2 (en) 2003-06-18 2005-05-26 Genelux Corporation Modified recombinant vaccina viruses and other microorganisms, uses thereof
WO2005005465A2 (en) * 2003-07-08 2005-01-20 Board Of Regents, University Of Texas System Methods and compositions to enhance immune responses via recall antigens
US8562970B2 (en) * 2003-10-08 2013-10-22 Sanofi Pasteur Limited Modified CEA/B7 vector
DK1989224T3 (da) * 2006-02-24 2011-02-14 Us Gov Health & Human Serv Immunogene peptider og anvendelsesmetoder
EP2207035B1 (de) 2006-03-14 2013-10-16 Oregon Health and Science University Methoden zur Detektion einer Mycobakterium tuberculosis Infektion
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
CN101528763B (zh) * 2006-08-30 2012-06-27 生物风险公司 分离和检测小多核苷酸的方法和物质
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
WO2008106551A2 (en) 2007-02-28 2008-09-04 The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Serv. Brachyury polypeptides and methods for use
WO2009006479A2 (en) 2007-07-02 2009-01-08 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
US7867483B2 (en) * 2007-10-18 2011-01-11 Bn Immunotherapeutics, Inc. Use of MVA to treat prostate cancer
JP5779352B2 (ja) 2008-03-14 2015-09-16 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 複製欠損フラビウイルスワクチンおよびワクチンベクター
US8691502B2 (en) * 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
CA2742049A1 (en) * 2008-10-31 2010-05-06 The Brigham And Women's Hospital, Inc. Vaccination with poxvirus vectors via mechanical epidermal disruption
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
JP5661738B2 (ja) * 2009-04-17 2015-01-28 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． 患者をモニターするためのバイオマーカー
EP3320915A1 (de) 2009-04-17 2018-05-16 Globeimmune, Inc. Kombinationsimmuntherapiezusammensetzungen gegen krebs sowie verfahren
EP3360566B1 (de) 2009-11-20 2019-12-25 Oregon Health&Science University Verfahren zum erkennen einer infektion mit dem mycobakterium tuberculosis
WO2012019125A2 (en) 2010-08-06 2012-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for prostate cancer and methods for their detection
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
PT2734544T (pt) 2011-07-18 2021-03-16 Us Health Métodos e composições para inibir a patologia associada a poliomavírus
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
WO2015095770A1 (en) 2013-12-20 2015-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic jc polyomavirus compositions and methods of use
AU2016205215B2 (en) 2015-01-09 2021-03-11 Etubics Corporation Methods and compositions for combination immunotherapy
KR20170102002A (ko) 2015-01-09 2017-09-06 이투빅스 코포레이션 에볼라 바이러스 백신접종을 위한 방법 및 조성물
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
SG11201803546WA (en) 2015-11-09 2018-05-30 Immune Design Corp Compositions comprising lentiviral vectors expressing il-12 and methods of use thereof
EP3400009A2 (de) 2016-01-05 2018-11-14 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Kombination von histondeacetylasehemmer und immuntherapie
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
CN111684198B (zh) * 2018-02-09 2022-09-23 株式会社龙野 填充装置
EP4464380A3 (de) 2018-12-04 2025-05-07 The Rockefeller University Hiv-impfstoff-immunogene
WO2023077147A2 (en) 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. T-cell vaccines for patients with reduced humoral immunity
US20230364227A1 (en) 2022-05-12 2023-11-16 Pellis Therapeutics, Inc. Poxvirus adjuvant for t-cell vaccination

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4514506A (en) 1982-02-23 1985-04-30 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5206353A (en) * 1988-07-23 1993-04-27 The United States Of America As Represented By The Department Of Health And Human Services CD-4/cytotoxic gene fusions
AU4058489A (en) 1988-08-08 1990-03-05 Michael A. Iffiu Collapsible recumbent bicycle with streamlined three-part folding canopy
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
EP0487587A1 (de) * 1989-08-18 1992-06-03 Chiron Corporation Rekombinante retroviren um vektorkonstruktionen an zielzellen zu liefern
US5126132A (en) * 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
CA2102623C (en) * 1991-05-06 2003-04-22 Jeffrey Schlom Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
KR960701988A (ko) * 1993-04-20 1996-03-28 윌리엄 에스. 로빈슨 세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents)
FR2710536B1 (fr) * 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
US20040091995A1 (en) 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses

Also Published As

Publication number Publication date
ES2336069T3 (es) 2010-04-08
EP2153846A1 (de) 2010-02-17
US7662395B2 (en) 2010-02-16
US20080279887A1 (en) 2008-11-13
US6045802A (en) 2000-04-04
DE69536039D1 (de) 2010-02-11

Similar Documents

Publication Publication Date Title
DE69536039D1 (de) Wirtszelle enthaltend ein rekombinantes Virus, welches ein Antigen exprimiert und ein rekombinantes Virus, welches ein immunstimulatorisches Molekül exprimiert
DE69519521D1 (de) Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
WO1996011279A3 (en) Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
MX9700229A (es) Vacuna de polinucleotido para virus de papiloma.
KR900700508A (ko) 인간의 호흡기 합포체성 바이러스에 대한 당단백질 면역 단편을 함유하는 키메라(chimeric) 당단백질
BR9712852A (pt) Plasmìdeo, composição, processo de imunização de um indivìduo contra um patógeno, vacina recombinante, patógeno vivo atenuado, proteìna bl-1 substancialmente pura, vetor recombinante de expressão, e, anticorpo isolado
PT1975235E (pt) Vacina de poxvírus recombinante contra o circovírus porcino
NO20012223D0 (no) Nukleotid og proteinsekvenser for NOGO-gener og fremgangsmåter basert derpå
PT93393A (pt) Processo para a preparacao de vacinas e de agentes de diagnostico que contem regioes imunogenicas de proteina e7do virus do papiloma humano do tipo 16 ou anticorpos suscitados contra estas regioes
ATE369428T1 (de) Behandlung von gebärmutterhalskrebs
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
DK22389D0 (da) Fremgangsmaade og middel til beskyttelse mod sygdomme foraarsaget af mikroorganismer, navnlig mycoplasma
HUP9801334A2 (hu) A 18-as típusú humán papillomavírust kódoló DNS
MA27699A1 (fr) Vaccin contre vhc
ATE401406T1 (de) Hühner-anaemie-virus mutante, impfstoffe, und verwendungen basiert auf virusprotein vp3, oder dafür kodierende virus-sequenzen
PT712926E (pt) Virus da doenca pancreatica do peixe
DK0507179T3 (da) Equine herpesvira (EHV), der indeholder fremmed
PT868522E (pt) Virus recombinante de poxvirus - virus da peritonite infecciosa felina, suas composicoes e metodos para a sua preparacao e utilizacao
EA200100700A1 (ru) Гены и белки и их применение
ATE404219T1 (de) Rekombinante poxvirus-calicivirus zusammensetzungen und anwendungen
MY101874A (en) Vaccine
DE60035485D1 (de) IDENTIFIZIERUNG VON SPEZIFISCHEN DIFFERENZIELL EXPRIMIERTEN ANTIGENEN AUS MYCOBACTERIUM UND MEDIZINISCHE VERWENDUNG DER MYCOBAKTERIUMPROTEINE Rv0068 UND Rv3407
IT1276765B1 (it) Gene del cromosoma x umano e proteina codificata da detto gene.
FI945110L (fi) Tippuribakteerien rokotteiden valmistusmenetelmä

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties